Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine

Bo Li,1,2 Michael Siuta,1 Vanessa Bright,1,2 Dmitry Koktysh,3,4 Brittany K Matlock,5 Megan E Dumas,1 Meiying Zhu,1 Alex Holt,1 Donald Stec,3,6 Shenglou Deng,7 Paul B Savage,7 Sebastian Joyce,8,9 Wellington Pham1,2,6,10–12 1Institute of Imaging Science, Vanderbilt University School of Medi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li B, Siuta M, Bright V, Koktysh D, Matlock BK, Dumas ME, Zhu M, Holt A, Stec D, Deng S, Savage PB, Joyce S, Pham W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Inhalable Nanoparticles Cancer Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/0dd026d1d3f145d0861a376f5c94fe1c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0dd026d1d3f145d0861a376f5c94fe1c
record_format	dspace
spelling	oai:doaj.org-article:0dd026d1d3f145d0861a376f5c94fe1c2021-12-02T01:46:42ZImproved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine1178-2013https://doaj.org/article/0dd026d1d3f145d0861a376f5c94fe1c2016-11-01T00:00:00Zhttps://www.dovepress.com/improved-proliferation-of-antigen-specific-cytolytic-t-lymphocytes-usi-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Bo Li,1,2 Michael Siuta,1 Vanessa Bright,1,2 Dmitry Koktysh,3,4 Brittany K Matlock,5 Megan E Dumas,1 Meiying Zhu,1 Alex Holt,1 Donald Stec,3,6 Shenglou Deng,7 Paul B Savage,7 Sebastian Joyce,8,9 Wellington Pham1,2,6,10–12 1Institute of Imaging Science, Vanderbilt University School of Medicine, 2Department of Radiology and Radiological Sciences, 3Department of Chemistry, Vanderbilt University, 4Vanderbilt Institute of Nanoscale Science and Engineering, 5Vanderbilt Flow Cytometry Shared Resource, Vanderbilt University, 6Vanderbilt Institute of Chemical Biology, 7Department of Chemistry and Biochemistry, Brigham Young University, 8Department of Pathology, Microbiology and Immunology, Vanderbilt University, 9Veterans Administration Tennessee Valley Healthcare System, 10Department of Biomedical Engineering, 11Vanderbilt Ingram Cancer Center, 12Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, USA Abstract: The present study investigated the immunoenhancing property of our newly designed nanovaccine, that is, its ability to induce antigen-specific immunity. This study also evaluated the synergistic effect of a novel compound PBS-44, an α-galactosylceramide analog, in boosting the immune response induced by our nanovaccine. The nanovaccine was prepared by encapsulating ovalbumin (ova) and an adjuvant within the poly(lactic-co-glycolic acid) nanoparticles. Quantitative analysis of our study data showed that the encapsulated vaccine was physically and biologically stable; the core content of our nanovaccine was found to be released steadily and slowly, and nearly 90% of the core content was slowly released over the course of 25 days. The in vivo immunization studies exhibited that the nanovaccine induced stronger and longer immune responses compared to its soluble counterpart. Similarly, intranasal inhalation of the nanovaccine induced more robust antigen-specific CD8+ T cell response than intraperitoneal injection of nanovaccine. Keywords: nanovaccine, dendritic cells, GalCer, inhalable vaccineLi BSiuta MBright VKoktysh DMatlock BKDumas MEZhu MHolt AStec DDeng SSavage PBJoyce SPham WDove Medical PressarticleInhalableNanoparticlesCancerMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 11, Pp 6103-6121 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Inhalable Nanoparticles Cancer Medicine (General) R5-920
spellingShingle	Inhalable Nanoparticles Cancer Medicine (General) R5-920 Li B Siuta M Bright V Koktysh D Matlock BK Dumas ME Zhu M Holt A Stec D Deng S Savage PB Joyce S Pham W Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine
description	Bo Li,1,2 Michael Siuta,1 Vanessa Bright,1,2 Dmitry Koktysh,3,4 Brittany K Matlock,5 Megan E Dumas,1 Meiying Zhu,1 Alex Holt,1 Donald Stec,3,6 Shenglou Deng,7 Paul B Savage,7 Sebastian Joyce,8,9 Wellington Pham1,2,6,10–12 1Institute of Imaging Science, Vanderbilt University School of Medicine, 2Department of Radiology and Radiological Sciences, 3Department of Chemistry, Vanderbilt University, 4Vanderbilt Institute of Nanoscale Science and Engineering, 5Vanderbilt Flow Cytometry Shared Resource, Vanderbilt University, 6Vanderbilt Institute of Chemical Biology, 7Department of Chemistry and Biochemistry, Brigham Young University, 8Department of Pathology, Microbiology and Immunology, Vanderbilt University, 9Veterans Administration Tennessee Valley Healthcare System, 10Department of Biomedical Engineering, 11Vanderbilt Ingram Cancer Center, 12Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, USA Abstract: The present study investigated the immunoenhancing property of our newly designed nanovaccine, that is, its ability to induce antigen-specific immunity. This study also evaluated the synergistic effect of a novel compound PBS-44, an α-galactosylceramide analog, in boosting the immune response induced by our nanovaccine. The nanovaccine was prepared by encapsulating ovalbumin (ova) and an adjuvant within the poly(lactic-co-glycolic acid) nanoparticles. Quantitative analysis of our study data showed that the encapsulated vaccine was physically and biologically stable; the core content of our nanovaccine was found to be released steadily and slowly, and nearly 90% of the core content was slowly released over the course of 25 days. The in vivo immunization studies exhibited that the nanovaccine induced stronger and longer immune responses compared to its soluble counterpart. Similarly, intranasal inhalation of the nanovaccine induced more robust antigen-specific CD8+ T cell response than intraperitoneal injection of nanovaccine. Keywords: nanovaccine, dendritic cells, GalCer, inhalable vaccine
format	article
author	Li B Siuta M Bright V Koktysh D Matlock BK Dumas ME Zhu M Holt A Stec D Deng S Savage PB Joyce S Pham W
author_facet	Li B Siuta M Bright V Koktysh D Matlock BK Dumas ME Zhu M Holt A Stec D Deng S Savage PB Joyce S Pham W
author_sort	Li B
title	Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine
title_short	Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine
title_full	Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine
title_fullStr	Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine
title_full_unstemmed	Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine
title_sort	improved proliferation of antigen-specific cytolytic t lymphocytes using a multimodal nanovaccine
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/0dd026d1d3f145d0861a376f5c94fe1c
work_keys_str_mv	AT lib improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine AT siutam improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine AT brightv improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine AT koktyshd improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine AT matlockbk improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine AT dumasme improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine AT zhum improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine AT holta improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine AT stecd improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine AT dengs improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine AT savagepb improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine AT joyces improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine AT phamw improvedproliferationofantigenspecificcytolytictlymphocytesusingamultimodalnanovaccine
_version_	1718402881038581760

Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine

Ejemplares similares